stock finance


Wells Fargo (WFC) has come a long way since its account-opening scandal–enough that it makes you wonder if that scandal has been forgotten on Wall Street. Not Argus analyst Stephen Biggar, who cut Wells Fargo today, arguing that the scandal remains an overhang for the banking giant following its earnings miss last week:

Agence France-Presse/Getty Images

We are downgrading Wells Fargo & Co. (NYSE: WFC) to HOLD from BUY following the companys 4Q earnings report and the recent sharp increase in the share price. WFC shares have more than recovered from their September 2016 selloff, which followed the revelation that bank employees had opened numerous fraudulent accounts to meet aggressive sales goals. In particular, bank employees opened new accounts with customer funds without disclosing this to customers…

stock finance: Select Medical Holdings Corporation(SEM)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Overvalued companies include MWI Veterinary (MWIV) andStericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but callsAratana (PETX) a “hidden gem.”

stock finance: Yanzhou Coal Mining Company Limited(YZC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Thursday afternoon, energy shares slipped by just 0.1 percent. Meanwhile, top gainers in the sector included Superior Energy Services, Inc. (NYSE: SPN), and Yanzhou Coal Mining Co Ltd (ADR) (NYSE: YZC).

stock finance: Infinity Pharmaceuticals, Inc.(INFI)


Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell by 0.98 percent. Meanwhile, top losers in the sector included Cleveland BioLabs, Inc. (NASDAQ: CBLI), down 25 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI), down 8 percent.

  • [By Lisa Levin]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dropped 70 percent to $1.32. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.

stock finance: Panhandle Royalty Company(PHX)


Advisors’ Opinion:

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Friday. Top gainers in the sector included Superior Energy Services, Inc. (NYSE: SPN), Panhandle Oil and Gas Inc. (NYSE: PHX), and SM Energy Co (NYSE: SM).

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

stock finance: Insys Therapeutics, Inc.(INSY)


Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell by 0.20 percent. Meanwhile, top losers in the sector included Horizon Pharma PLC (NASDAQ: HZNP), down 20 percent, and Insys Therapeutics Inc (NASDAQ: INSY), down 17 percent.

  • [By Sean Williams]

    Shares of Insys Therapeutics (NASDAQ:INSY), a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%. The reason for the volatile trading can probably be traced to carryover from the company’s first-quarter earnings release before the opening bell on Tuesday.

  • [By Keith Speights]

    There are plenty of reasons for investors to like three marijuana stocks in particular — GW Pharmaceuticals (NASDAQ:GWPH), Insys Therapeutics (NASDAQ:INSY), and Aphria (NASDAQOTH:APHQF). In fact, there are at least 661 million reasons. That’s the amount of cash in U.S. dollars that the three companies have combined. Here’s why the cash stockpiles held by GW, Insys, and Apria are important.

  • [By Keith Speights]

    Insys Therapeutics (NASDAQ:INSY) already won U.S. regulatory approval fordronabinol solution Syndros in treatingchemotherapy-induced nausea and vomiting (CINV) and anorexia in patients with AIDS. The company is preparing to launch Syndros soon.

Leave a Reply

Your email address will not be published. Required fields are marked *